Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats
Abstract
The finding that serotonin (5-HT) can modulate dopamine (DA) and norepinephrine (NE) release in the brain has led us to hypothesize that fluoxetine, a selective 5-HT reuptake inhibitor, may influence the ability of bupropion, a preferential DA and NE dual reuptake inhibitor, to modulate extracellular DA and NE concentrations in some brain areas. The present study was designed to evaluate this hypothesis by assessing the effects of fluoxetine on bupropion-induced changes in extracellular monoamine concentrations by means of in vivo microdialysis. Three mesocorticolimbic areas including hypothalamus (Ht), prefrontal cortex (Pfc) and nucleus accumbens (Acb) were selected based on their relevance to depression and antidepressant actions. In the Ht of untreated rats, bupropion dose-dependently (s.c.) increased extracellular DA and NE concentrations either in single injection study or in sequential injection study. Thus, 10 mg/kg of bupropion had no effect on the DA and NE concentrations, while 30 mg/kg of bupropion induced transient but significant increases (about 240% of the baselines), and 100 mg/kg of bupropion induced marked and persistent increases (over 600% of the baselines) in the DA and NE concentrations. In the rats pre-treated with fluoxetine (10 mg/kg, s.c., 90 min interval), the threshold dose of bupropion (10 mg/kg) significantly increased the DA and NE concentrations to more than 350% of the baselines, and 30 mg/kg of bupropion markedly increased the DA and NE concentrations to more than 570% of the baselines in the Ht. The fluoxetine pre-treatment also potentiated the DA increases induced by 10 mg/kg of bupropion in the Pfc (260% for bupropion alone vs 357% for the combination) and in the Acb (224% vs 645%). The bupropion-induced NE increases were potentiated by fluoxetine mainly in the Ht. Bupropion did not significantly affect the extracellular 5-HT concentrations in all the 3 brain areas tested. In summary, the present study demonstrated that bupropion can increase extracellular DA and NE concentrations in several mesocorticolimbic areas, which may have an impact on bupropion's antidepressant actions. Furthermore, fluoxetine can potentiate the bupropion-induced DA and NE increases, which may produce more effective and rapid antidepressant actions.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Bupropion treatment increases extracellular concentrations of DA and NE in the hypothalamus, PFC, and NAcc.
“Microdialysis studies indicate that bupropion treatment increases extracellular concentrations of DA and norepinephrine (NE) in the hypothalamus, PFC, and NAcc [216].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [216]
Cites
The rat brain in stereotaxic coordinates
Palkovits, M. (1983) · Neuropeptides · doi:10.1016/0143-4179(83)90049-5 · Cited by 28,959 · see citing works
The Rat Brain in Stereotaxic Coordinates
Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585 · see citing works
Bupropion: a review of its mechanism of antidepressant activity.
Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., & Richelson, E. (1995) · PubMed · Cited by 680 · see citing works
Wong, D. T., Horng, J. S., Bymaster, F. P., Hauser, K. L., & Molloy, B. B. (1974) · Life Sciences · doi:10.1016/0024-3205(74)90345-2 · Cited by 480 · see citing works
Crewe, H. K., Lennard, M., Tucker, G., Woods, F. R., & Haddock, R. E. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04134.x · Cited by 468 · see citing works
Hervé, D., Pickel, V. M., JOH, T. H., & Beaudet, A. (1987) · Brain Research · doi:10.1016/0006-8993(87)91588-5 · Cited by 372 · see citing works
Morphological and Functional Aspects of Central Monoamine Neurons
Fuxé, K., Hökfelt, T. G. M., & Ungerstedt, U. (1970) · International review of neurobiology · doi:10.1016/s0074-7742(08)60167-1 · Cited by 352 · see citing works
Tanda, G., Carboni, E., Frau, R., & Chiara, G. D. (1994) · Psychopharmacology · doi:10.1007/bf02244785 · Cited by 320 · see citing works
Millan, M. J., Dekeyne, A., & Gobert, A. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00078-1 · Cited by 283 · see citing works
Dopamine and depression: A review of recent evidence. I. Empirical studies
Willner, P. (1983) · Brain Research Reviews · doi:10.1016/0165-0173(83)90005-x · Cited by 273 · see citing works
Inhibition by fluoxetine of cytochrome P450 2D6 activity
Otton, S. V., Wu, D., Joffe, R. T., Cheung, S. W., & Sellers, E. M. (1993) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1993.43 · Cited by 258 · see citing works
Parsons, L. H., & Justice, J. B. (1993) · Brain Research · doi:10.1016/0006-8993(93)90984-u · Cited by 253 · see citing works
Rénéric, J.-P., & Lucki, I. (1998) · Psychopharmacology · doi:10.1007/s002130050555 · Cited by 249 · see citing works
Perry, K. W., & Fuller, R. W. (1992) · Life Sciences · doi:10.1016/0024-3205(92)90423-m · Cited by 219 · see citing works
Cooper, B. R., Hester, T. J., & Maxwell, R. A. (1980) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32266-4 · Cited by 213 · see citing works
The mesolimbic dopamine system as a target for rapid antidepressant action
Willner, P. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199707003-00002 · Cited by 209 · see citing works
Fuller, R. W., Perry, K. W., & Molloy, B. B. (1974) · Life Sciences · doi:10.1016/s0024-3205(74)80012-3 · Cited by 207 · see citing works
Cooper, B. R., Wang, C. M., Cox, R. F., Norton, R. M., Shea, V., & Ferris, R. M. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.43 · Cited by 184 · see citing works
Gobert, A., & Millan, M. J. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(98)00188-9 · Cited by 171 · see citing works
Bodkin, J. A., Lasser, R. A., Wines, J. D., Gardner, D. M., & Baldessarini, R. J. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0401 · Cited by 159 · see citing works
Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization.
Iyer, R. N., & Bradberry, C. W. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12836-x · Cited by 131 · see citing works
Nomikos, G. G. (1989) · Neuropsychopharmacology · doi:10.1016/0893-133x(89)90031-6 · Cited by 131 · see citing works
Studies of bupropion's mechanism of antidepressant activity.
Ferris, R. M., Cooper, B. R., & Maxwell, R. A. (1983) · PubMed · Cited by 127 · see citing works
Richelson, E. (1997) · Mayo Clinic Proceedings · doi:10.4065/72.9.835 · Cited by 127 · see citing works
Metabolism and kinetics of bupropion.
Dh, S. (1983) · PubMed · Cited by 121 · see citing works
Nomikos, G. G., Damsma, G., Wenkstern, D., & Fibiger, H. C. (1992) · PubMed · Cited by 109 · see citing works
Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
Feighner, J. P., Gardner, E. A., Johnston, J. A., Batey, S. R., Khayrallah, M. A., Ascher, J. A., & Lineberry, C. G. (1991) · PubMed · Cited by 107 · see citing works
The role of noradrenaline in depression: a review.
Leonard, B. E. (1997) · PubMed · Cited by 101 · see citing works
Sulser, F. (1987) · PubMed · Cited by 98 · see citing works
Carbamazepine but not Valproate Induces Bupropion Metabolism
Ketter, T. A., Jenkins, J. B., Schroeder, D. H., Pazzaglia, P. J., Marangell, L. B., George, M. S., Callahan, A. M., Hinton, M. L., Chao, J. Y., & Post, R. M. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199510000-00004 · Cited by 94 · see citing works
Sorensen, S. M., Humphreys, T. M., & Palfreyman, M. G. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90402-0 · Cited by 92 · see citing works
Rampello, L., Nicoletti, G. F., & Raffaele, R. (1991) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1991.tb03193.x · Cited by 86 · see citing works
Feuerstein, T. J., & Hertting, G. (1986) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00512929 · Cited by 85 · see citing works
Pharmacological significance of the species differences in bupropion metabolism
Welch, R. M., Lai, A. A., & Schroeder, D. H. (1987) · Xenobiotica · doi:10.3109/00498258709043939 · Cited by 80 · see citing works
Golden, R. N. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800260047006 · Cited by 78 · see citing works
Antidepressant Profile of Bupropion and three Metabolites in Mice
Martin, P., Massol, J., Colin, J. N., Lacomblez, L., & Puech, A. J. (1990) · Pharmacopsychiatry · doi:10.1055/s-2007-1014505 · Cited by 71 · see citing works
SAMANIN, R., Bernasconi, S., & Garattini, S. K. (1975) · European Journal of Pharmacology · doi:10.1016/0014-2999(75)90266-6 · Cited by 69 · see citing works
Perry, K. W., & Fuller, R. W. (1993) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1993.tb07105.x · Cited by 63 · see citing works
Matsumoto, M., Togashi, H., Mori, K., Ueno, K., Miyamoto, A., & Yoshioka, M. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00636-6 · Cited by 62 · see citing works
Perry, K. W., & Fuller, R. W. (1997) · Journal of Neural Transmission · doi:10.1007/bf01285563 · Cited by 60 · see citing works
A double‐blind study of L‐sulpiride versus amitriptyline in lithium‐maintained bipolar depressives
Bocchetta, A., Bernardi, F., Burrai, C., Pedditzi, M., & Zompo, M. D. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03487.x · Cited by 60 · see citing works
Saito, H., Matsumoto, M., Togashi, H., & Yoshioka, M. (1996) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.70.203 · Cited by 58 · see citing works
Ring, B. J., Binkley, S. N., Roskos, L. K., & Wrighton, S. A. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12163-0 · Cited by 57 · see citing works
Development of Antidepressant Drugs
Wong, D. T., & Bymaster, F. P. (1995) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-1857-0_11 · Cited by 52 · see citing works
Selective Serotonin/Noradrenaline Reuptake Inhibitors (SNRIs)
Artigas, F. (1995) · CNS Drugs · doi:10.2165/00023210-199504020-00001 · Cited by 44 · see citing works
Dopamine Autoreceptor Agonists in the Treatment of Schizophrenia and Major Depression*
Benkert, O., Gründer, G., & Wetzel, H. (1992) · Pharmacopsychiatry · doi:10.1055/s-2007-1014417 · Cited by 40 · see citing works
Wong, D. T., & Bymaster, F. P. (1995) · PubMed · Cited by 38 · see citing works
Arnt, J., Christensen, A. V., & Hyttel, J. (1985) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00501197 · Cited by 37 · see citing works
Pharmacology of amineptine, an antidepressant agent acting on the dopaminergic system
Garattini, S. K. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199707003-00003 · Cited by 34 · see citing works
Gandolfi, O., Barbaccia, M. L., Chuang, D. M., & Costa, E. (1983) · Neuropharmacology · doi:10.1016/0028-3908(83)90143-0 · Cited by 34 · see citing works
Bryant, S. G., Guernsey, B. G., & Ingrim, N. B. (1983) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/40.12.2241 · Cited by 24 · see citing works
Bupropion and sertraline combination treatment in refractory depression
Marshall, R. D., Johannet, C. M., Collins, P. Y., Smith, H. E., Kahn, D. A., & Douglas, C. J. (1995) · Journal of Psychopharmacology · doi:10.1177/026988119500900313 · Cited by 21 · see citing works
Li, X., Perry, K. W., & Fuller, R. W. (1996) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1996.tb03982.x · Cited by 13 · see citing works
Firestone, J. A., Gerhardt, G. A., DeBernardis, J. F., McKelvy, J. F., & Browning, M. D. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10132-8 · Cited by 11 · see citing works
Effect of bupropion on dopamine and 5-hydroxytryptamine-mediated behaviour in mice
Muley, M. P., Joshi, M., & Manekar, M. S. (1984) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1984.tb06944.x · Cited by 11 · see citing works
Smiałowski, A. (1987) · Journal of Neural Transmission · doi:10.1007/bf01244341 · Cited by 7 · see citing works
Pileblad, E., & Engberg, G. (1986) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00569374 · Cited by 7 · see citing works
Noradrenaline in depression: half a century of progress.
Nutt, D. (1997) · PubMed · Cited by 6 · see citing works
Flagged first, then by citations
2 of the 60 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics
Sonuga-Barke, E. J. S. (2003) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2003.08.005 · Cited by 816 · see citing works
Stahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S. (2004) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v06n0403 · Cited by 495 · see citing works
The Role of Nicotine in Smoking: A Dual-Reinforcement Model
Caggiula, A. R., Donny, E. C., Palmatier, M. I., Liu, X., Chaudhri, N., & Sved, A. F. (2008) · Nebraska Symposium on Motivation · doi:10.1007/978-0-387-78748-0_6 · Cited by 226 · see citing works
Mazloum‐Ardakani, M., Beitollahi, H., Amini, M. K., Mirkhalaf, F., & Abdollahi‐Alibeik, M. (2010) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2010.09.011 · Cited by 224 · see citing works
Cryan, J. F., Bruijnzeel, A. W., Skjei, K. L., & Markou, A. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1445-7 · Cited by 223 · see citing works
Gadad, B. S., Jha, M. K., Czysz, A., Furman, J. L., Mayes, T. L., Emslie, M. P., & Trivedi, M. H. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.07.001 · Cited by 205 · see citing works
Wilens, T. E., Haight, B. R., Horrigan, J. P., Hudziak, J. J., Rosenthal, N. E., Connor, D. F., Hampton, K. D., Richard, N. E., & Modell, J. G. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.027 · Cited by 193 · see citing works
Pizzagalli, D. A., Webb, C. A., Dillon, D. G., Tenke, C. E., Kayser, J., Goer, F., Fava, M., McGrath, P., Weissman, M., Parsey, R., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0252 · Cited by 189 · see citing works
Dopaminergic-based pharmacotherapies for depression
Papakostas, G. I. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.12.002 · Cited by 168 · see citing works
Has dopamine a physiological role in the control of sexual behavior?
Paredes, R. G., & Ågmo, A. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.001 · Cited by 163 · see citing works
Carroll, F. I., Blough, B. E., Abraham, P., Mills, A. C., Holleman, J. A., Wolckenhauer, S. A., Decker, A. M., Landavazo, A., McElroy, K. T., Navarro, H. A., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901189z · Cited by 161 · see citing works
A role for cannabinoid CB1 receptors in mood and anxiety disorders
Witkin, J. M., Tzavara, E. T., & Nomikos, G. G. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00005 · Cited by 156 · see citing works
Relevance of Norepinephrine–Dopamine Interactions in the Treatment of Major Depressive Disorder
Mansari, M. E., Guiard, B. P., Chernoloz, O., Ghanbari, R., Katz, N., & Blier, P. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00146.x · Cited by 146 · see citing works
Bruijnzeel, A. W., & Markou, A. (2003) · Synapse · doi:10.1002/syn.10242 · Cited by 143 · see citing works
Assessing the effects of bupropion SR on mood dimensions of depression
Tomarken, A. J., Dichter, G. S., Freid, C., Addington, S., & Shelton, R. C. (2004) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00306-3 · Cited by 139 · see citing works
Kitaichi, Y., Inoue, T., Nakagawa, S., Boku, S., Kakuta, A., Izumi, T., & Koyama, T. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.08.026 · Cited by 136 · see citing works
Extending the Role of Associative Learning Processes in Nicotine Addiction
Bevins, R. A., & Palmatier, M. I. (2004) · Behavioral and Cognitive Neuroscience Reviews · doi:10.1177/1534582304272005 · Cited by 123 · see citing works
Beitollahi, H., & Sheikhshoaie, I. (2011) · Journal of Electroanalytical Chemistry · doi:10.1016/j.jelechem.2011.08.014 · Cited by 122 · see citing works
Carroll, F. I., Blough, B. E., Mascarella, S. W., Navarro, H. A., Eaton, J. B., Lukas, R. J., & Damaj, M. I. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9017465 · Cited by 119 · see citing works
Salmanpour, S., Tavana, T., Pahlavan, A., Khalilzadeh, M. A., Ensafi, A. A., Karimi‐Maleh, H., Beitollahi, H., Kowsari, E., & Zareyee, D. (2012) · Materials Science and Engineering C · doi:10.1016/j.msec.2012.05.038 · Cited by 111 · see citing works
Thielen, R. J., Engleman, E. A., Rodd, Z. A., Murphy, J. M., Lumeng, L., Li, T., & McBride, W. J. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.059790 · Cited by 106 · see citing works
Preclinical and Clinical Pharmacology of DOV 216,303, a “Triple” Reuptake Inhibitor
Skolnick, P., Krieter, P. A., Tizzano, J. P., Basile, A. S., Popik, P., Czobor, P., & LIPPA, A. S. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00123.x · Cited by 105 · see citing works
Chiamulera, C. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.08.005 · Cited by 101 · see citing works
Beitollahi, H., & Mohammadi, S. (2013) · Materials Science and Engineering C · doi:10.1016/j.msec.2013.03.050 · Cited by 95 · see citing works
Akhgar, M. R., Beitollahi, H., Salari, M., Karimi‐Maleh, H., & Zamani, H. A. (2011) · Analytical Methods · doi:10.1039/c1ay05503h · Cited by 95 · see citing works
Mazloum‐Ardakani, M., Beitollahi, H., Sheikh‐Mohseni, M. A., Naeimi, H., & Taghavinia, N. (2010) · Applied Catalysis A General · doi:10.1016/j.apcata.2010.02.019 · Cited by 95 · see citing works
Mazloum‐Ardakani, M., Sheikh‐Mohseni, M. A., Abdollahi‐Alibeik, M., & Benvidi, A. (2012) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2012.04.071 · Cited by 95 · see citing works
Inhibitory Control Deficits in Rats with Ventral Hippocampal Lesions
Abela, A. R., Dougherty, S. D., Fagen, E. D., Hill, C. J. R., & Chudasama, Y. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhs121 · Cited by 94 · see citing works
Bijlsma, E. Y., Chan, J. S. W., Olivier, B., Veening, J. G., Millan, M. J., Waldinger, M. D., & Oosting, R. S. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.10.004 · Cited by 88 · see citing works
Paterson, N. E., Balfour, D. J. K., & Markou, A. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05546.x · Cited by 80 · see citing works
Arias, H. R. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.05.015 · Cited by 77 · see citing works
Liu, X., Caggiula, A. R., Palmatier, M. I., Donny, E. C., & Sved, A. F. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0967-9 · Cited by 77 · see citing works
Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion
Cryan, J. F., Gasparini, F., Heeke, G. V., & Markou, A. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02890-3 · Cited by 76 · see citing works
McKittrick, C. R., & Abercrombie, E. D. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04300.x · Cited by 75 · see citing works
Bupropion for Overweight Women With Binge-Eating Disorder
White, M. A., & Grilo, C. M. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08071 · Cited by 75 · see citing works
Cellular, molecular, and genetic substrates underlying the impact of nicotine on learning
Gould, T. J., & Leach, P. T. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.08.004 · Cited by 68 · see citing works
Kobayashi, T., Hayashi, E., Shimamura, M., Kinoshita, M., & Murphy, N. P. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1070-6 · Cited by 67 · see citing works
Mechanistic insights into nicotine withdrawal
Paolini, M., & De Biasi, M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.07.075 · Cited by 66 · see citing works
Bymaster, F. P., Gołembiowska, K., Kowalska, M., Choi, Y. K., & Tarazi, F. I. (2012) · Synapse · doi:10.1002/syn.21538 · Cited by 65 · see citing works
El Mansari, M., Ghanbari, R., Janssen, S., & Blier, P. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.028 · Cited by 63 · see citing works
Yi, L., Li, J., Li, H.-C., Su, D.-X., Quan, X.-B., He, X.-C., & Wang, X. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.009 · Cited by 62 · see citing works
Bubar, M. J., McMahon, L. R., Deurwaerdère, P. D., Spampinato, U., & Cunningham, K. A. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(02)00381-7 · Cited by 62 · see citing works
Need, A. B., Davis, R. J., Alexander-Chacko, J. T., Eastwood, B. J., Chernet, E., Phebus, L. A., Sindelar, D. K., & Nomikos, G. G. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0234-x · Cited by 61 · see citing works
Narayana, P. V., Reddy, T. M., Gopal, P., Reddy, M. M., & Naidu, G. R. K. (2015) · Materials Science and Engineering C · doi:10.1016/j.msec.2015.06.011 · Cited by 60 · see citing works
Specificity and impact of adrenergic projections to the midbrain dopamine system
Mejías-Aponte, C. A. (2016) · Brain Research · doi:10.1016/j.brainres.2016.01.036 · Cited by 58 · see citing works
Silvagni, A., Barros, V. G., Mura, C., Antonelli, M. C., & Carboni, E. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06364.x · Cited by 58 · see citing works
Neurochemical and Psychotropic Effects of Bupropion in Healthy Male Subjects
Gobbi, G., Slater, S., Boucher, N., Debonnel, G., & Blier, P. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000084023.22282.03 · Cited by 56 · see citing works
ADHD: Current and Future Therapeutics
Heal, D. J., Smith, S. L., & Findling, R. L. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_125 · Cited by 54 · see citing works
Bourin, M., Chenu, F., Prica, C., & Hascoët, M. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1583-7 · Cited by 57 · see citing works
Nasirizadeh, N., & Zare, H. R. (2009) · Talanta · doi:10.1016/j.talanta.2009.07.044 · Cited by 53 · see citing works
Neurophysiology of Nicotine Addiction
Dani, J. A., Jenson, D., & Broussard, J. I. (2012) · Journal of Addiction Research & Therapy · doi:10.4172/2155-6105.s1-001 · Cited by 53 · see citing works
Bupropion dose-dependently reverses nicotine withdrawal deficits in contextual fear conditioning
Portugal, G. S., & Gould, T. J. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.08.004 · Cited by 51 · see citing works
A New Strategy for Antidepressant Prescription
Lavergne, F., & Jay, T. M. (2010) · Frontiers in Neuroscience · doi:10.3389/fnins.2010.00192 · Cited by 50 · see citing works
Engleman, E. A., Ingraham, C. M., McBride, W. J., Lumeng, L., & Murphy, J. M. (2006) · Alcohol · doi:10.1016/j.alcohol.2006.03.001 · Cited by 50 · see citing works
Bupropion and sertraline enhance retrieval of recent and remote long-term memory in rats
Barros, D. M., Izquierdo, L. A., Medina, J. H., & Izquierdo, I. (2002) · Behavioural Pharmacology · doi:10.1097/00008877-200205000-00004 · Cited by 48 · see citing works
Functional Brain Changes in Response to Treatment of Internet Gaming Disorder
Han, D. H., Kim, S. M., & Renshaw, P. F. (2015) · Studies in neuroscience, psychology and behavioral economics · doi:10.1007/978-3-319-07242-5_5 · Cited by 47 · see citing works
Antidepressant-like effects of selegiline in the forced swim test
Shimazu, S., Minami, A., Kusumoto, H., & Yoneda, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.02.003 · Cited by 45 · see citing works
Noradrenaline is necessary for the hedonic properties of addictive drugs
Jasmin, L., Mena, N., & Tien, D. A. (2006) · Vascular Pharmacology · doi:10.1016/j.vph.2005.08.030 · Cited by 43 · see citing works
Endogenous dopaminergic modulation of the lamprey spinal locomotor network
Svensson, E., Woolley, J. D., Wikström, M. A., & Grillner, S. E. (2003) · Brain Research · doi:10.1016/s0006-8993(02)04216-6 · Cited by 43 · see citing works
Kitamura, Y., Yagi, T., Kitagawa, K., Shinomiya, K., Kawasaki, H., Asanuma, M., & Gomita, Y. (2010) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-010-0521-x · Cited by 41 · see citing works
Palmatier, M. I., Levin, M. E., Mays, K. L., Donny, E. C., Caggiula, A. R., & Sved, A. F. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1666-5 · Cited by 40 · see citing works
Lengyel, K. D., Pieschl, R. L., Strong, T., Molski, T. F. P., Mattson, G. K., Lodge, N. J., & Li, Y.-W. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.04.014 · Cited by 40 · see citing works
Wu, C., Li, J., Liu, X., Zhang, H., Li, R., Wang, G., Wang, Z., Li, Q., & Shangguan, E. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.111557 · Cited by 37 · see citing works
Paterson, N. E. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.12.009 · Cited by 36 · see citing works
Molina-Hernández, M., Téllez-Alcántara, N. P., García, J. P., Lopez, J. I. O., & Jaramillo, M. T. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.11.017 · Cited by 37 · see citing works
Yeniceli, D., Şener, E., Korkmaz, O. T., Doğrukol‐Ak, D., & Tunçel, N. (2010) · Talanta · doi:10.1016/j.talanta.2010.11.063 · Cited by 35 · see citing works
Ghanbari, R., Mansari, M. E., & Blier, P. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2260-1 · Cited by 35 · see citing works
Gould, G. G., Pardon, M., Morilak, D. A., & Frazer, A. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300236 · Cited by 35 · see citing works
Triple Reuptake Inhibitors (“Broad Spectrum” Antidepressants)
Skolnick, P., & Basile, A. S. (2007) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152707780363285 · Cited by 35 · see citing works
Svensson, E., Wikström, M. A., Hill, R. H., & Grillner, S. E. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02466.x · Cited by 35 · see citing works
Wei, B., Li, Q., Fan, R., Su, D., Xiu-li, O., Chen, K., Chen, X., Jia, Y., & Bi, K. (2013) · Journal of Mass Spectrometry · doi:10.1002/jms.3176 · Cited by 34 · see citing works
Beitollahi, H., Mohadesi, A., Mahani, S. K., Karimi‐Maleh, H., & Akbari, A. (2012) · Ionics · doi:10.1007/s11581-012-0669-0 · Cited by 34 · see citing works
Liu, X. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3145-2 · Cited by 34 · see citing works
Goyal, R. N., Rana, A. R. S., Aziz, M. A., & Oyama, M. (2011) · Analytica Chimica Acta · doi:10.1016/j.aca.2011.03.026 · Cited by 34 · see citing works
Dhir, A., & Kulkarni, S. K. (2008) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00605.x · Cited by 32 · see citing works
Egerton, A., Shotbolt, J. P., Stokes, P. R. A., Hirani, E., Ahmad, R., Lappin, J., Reeves, S., Mehta, M. A., Howes, O. D., & Grasby, P. M. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.11.077 · Cited by 31 · see citing works
Aspirin Curtails the Acetaminophen-Induced Rise in Brain Norepinephrine Levels
Maharaj, H., Maharaj, D. S., Saravanan, K. S., Mohanakumar, K. P., & Daya, S. (2004) · Metabolic Brain Disease · doi:10.1023/b:mebr.0000027418.33772.8b · Cited by 31 · see citing works
Guiard, B. P., Chenu, F., Mansari, M. E., & Blier, P. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000076 · Cited by 31 · see citing works
Rational site-directed pharmacotherapy for major depressive disorder
Blier, P. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000400 · Cited by 29 · see citing works
Gołembiowska, K., Kowalska, M., & Bymaster, F. P. (2011) · Synapse · doi:10.1002/syn.21531 · Cited by 30 · see citing works
Heal, D. J., & Smith, S. L. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211032475 · Cited by 31 · see citing works
Mahmoudi‐Moghaddam, H., & Beitollahi, H. (2011) · International Journal of Electrochemical Science · doi:10.1016/s1452-3981(23)19696-9 · Cited by 30 · see citing works
Ghanbari, R., Mansari, M. E., & Blier, P. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108095714 · Cited by 30 · see citing works
Chenu, F., Mansari, M. E., & Blier, P. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009218 · Cited by 30 · see citing works
Semba, J., & Wakuta, M. (2008) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2008.01822.x · Cited by 28 · see citing works
Brain Norepinephrine System as a Target for Antidepressant and Mood Stabilizing Medications
Dremencov, E., Mansari, M. E., & Blier, P. (2009) · Current Drug Targets · doi:10.2174/138945009789735165 · Cited by 29 · see citing works
Fletcher, P. J., Sinyard, J., Salsali, M., & Baker, G. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1747-9 · Cited by 28 · see citing works
Paterson, N. E. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32832c7083 · Cited by 27 · see citing works
Bupropion effects on aggressiveness and anxiety in OF1 male mice
Redolat, R., G�mez, M. C., Vicens, P., & Carrasco, M. C. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1965-9 · Cited by 27 · see citing works
Age differences in an animal model of obsessive–compulsive disorder: participation of dopamine
Ulloa, R. E., Nicolini, H., & Fernández‐Guasti, A. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.04.009 · Cited by 27 · see citing works
de Almeida, G. R. L., Szczepanik, J. C., Selhorst, I., Schmitz, A. E., dos Santos, B., Cunha, M. P., Heinrich, I. A., de Paula, G. C., Bem, A. F. D., Leal, R. B., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02146-3 · Cited by 25 · see citing works
Marek, G. J. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(06)78006-0 · Cited by 25 · see citing works
Cavariani, M. M., Kiguti, L. R. D. A., Rosa, J. D. L., Leite, G. A. A., Silva, P. V. E., Pupo, A. S., & Kempinas, W. D. G. (2015) · Journal of Applied Toxicology · doi:10.1002/jat.3089 · Cited by 25 · see citing works
Bupropion increases activation in nucleus accumbens during anticipation of monetary reward
Ikeda, Y., Funayama, T., Tateno, A., Fukayama, H., Okubo, Y., & Suzuki, H. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05337-6 · Cited by 26 · see citing works
Characterization of the transporterB0AT3 (Slc6a17) in the rodent central nervous system
Hägglund, M. G., Hellsten, S. V., Bagchi, S., Ljungdahl, A., Nilsson, V. C., Winnergren, S., Stephansson, O., Rumaks, J., Svirskis, Š., Klusa, V. Z., et al. (2013) · BMC Neuroscience · doi:10.1186/1471-2202-14-54 · Cited by 22 · see citing works
Biała, G., & Kruk, M. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70027-1 · Cited by 24 · see citing works
A Novel Antidepressant-like Action of Drugs Possessing GIRK Channel Blocking Action in Rats
Kawaura, K., Honda, S., Soeda, F., SHIRASAKI, T., & Takahama, K. (2010) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.130.699 · Cited by 24 · see citing works
Dopamine and Serotonin Interactively Modulate Prefrontal Cortex Neurons In Vitro
Pietro, N. C. D., & Seamans, J. K. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.007 · Cited by 23 · see citing works
Pharmacological characterisation of the thermogenic effect of bupropion
Liu, Y.-L., Connoley, I. P., Heal, D. J., & Stock, M. J. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.004 · Cited by 23 · see citing works
Cordery, P., Peirce, N. S., Maughan, R. J., & Watson, P. (2016) · Scandinavian Journal of Medicine and Science in Sports · doi:10.1111/sms.12753 · Cited by 22 · see citing works
- Authors
- Li, S. X.-M., Perry, K. W., & Wong, D. T.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Perry, Kenneth W
- ORCID
- Wong, David T
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2002-02
- Volume
- 42
- Issue
- 2
- Pages
- 181-190
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W1971669832
- Cited by
- 156
- References
- 60
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2021: 2 · 2020: 5 · 2019: 3 · 2018: 3 · 2017: 5 · 2016: 4 · 2015: 4 · 2014: 4 · 2013: 14 · 2012: 11
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- fluoxetine, bupropion, extracellular dopamine, serotonin, mesocorticolimbic system, hypothalamus, prefrontal cortex, nucleus accumbens, monoamine release, antidepressant mechanism, selective serotonin reuptake inhibitors, depression, drug interactions, microdialysis, rats
- MeSH terms
- Animals, Cerebral Cortex, Chromatography, High Pressure Liquid, Dopamine, Extracellular Space, Fluoxetine, Hematocrit, Limbic System, Male, Norepinephrine, Bupropion, Rats, Sprague-Dawley, Selective Serotonin Reuptake Inhibitors, Microdialysis, Dopamine Uptake Inhibitors, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review